% Generated by roxygen2: do not edit by hand
% Please edit documentation in R/data_doc.R
\docType{data}
\name{imvigor210_pdata}
\alias{imvigor210_pdata}
\title{IMvigor210 Bladder Cancer Immunotherapy Cohort Data}
\format{
A data frame with patients as rows and variables as columns:
\describe{
  \item{ID}{Patient sample identifier}
  \item{BOR}{Best overall response (CR, PR, SD, PD, NA)}
  \item{BOR_binary}{Binary response classification (R=responder,
  NR=non-responder)}
  \item{OS_days}{Overall survival time in days}
  \item{OS_status}{Overall survival status (0=alive, 1=dead)}
  \item{Mutation_Load}{Tumor mutation burden}
  \item{Neo_antigen_Load}{Neoantigen load}
  \item{CD_8_T_effector}{CD8+ T effector signature score}
  \item{Immune_Checkpoint}{Immune checkpoint signature score}
  \item{Pan_F_TBRs}{Pan-fibroblast TGF-\eqn{\beta} response signature}
  \item{Mismatch_Repair}{Mismatch repair status or signature}
  \item{TumorPurity}{Estimated tumor purity}
}
}
\source{
IMvigor210 clinical trial (NCT02108652)
}
\usage{
data(imvigor210_pdata)
}
\description{
Clinical and biomarker data from the IMvigor210 clinical trial cohort.
Includes treatment response, survival outcomes, and immune biomarker
measurements for bladder cancer patients treated with atezolizumab.
}
\examples{
data(imvigor210_pdata)
head(imvigor210_pdata)
}
\references{
Mariathasan S et al. TGF\eqn{\beta} attenuates tumour response to PD-L1 blockade
by contributing to exclusion of T cells. Nature 554, 544-548 (2018).
doi:10.1038/nature25501
}
\keyword{datasets}
